Ketamine for depression: all studies (page 78)

Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Australian & New Zealand Journal of Psychiatry October 1, 2024 Alistair Carroll, Adam Bayes, Mark Montebello et al. 10 citations

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...

DOI: 10.1177/00048674241242315 Full text Drug dependence Regulations Ketamine therapy Mental health treatment +3

Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.

Psychiatry Research October 1, 2024 Je-Yeon Yun, Yong‐Ku Kim 11 citations

Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...

DOI: 10.1016/j.psychres.2024.116092 Full text Treatment-resistant depression Anhedonia Magnetic resonance imaging Suicidality +6

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

DOI: 10.1016/j.psychres.2024.116125 Full text Major depressive disorder Antidepressant effect Depressive symptoms Psychopharmacology +8

Inflammatory cytokines, cortisol, and anhedonia in patients with treatment-resistant depression after consecutive infusions of low-dose esketamine.

European Archives of Psychiatry and Clinical Neuroscience September 28, 2024 Yue Wang, Qiongyao Yang, Chuanchuan Chen et al. 10 citations

Anhedonia, defined as a significant loss of interest or pleasure, is one of the core symptoms of treatment- resistant depression (TRD) and is often associated with poor prognosis. This article primarily investigates the changes in anhedonia symptoms, inflammatory markers, and cortisol levels in TRD patients after low-dose esketamine treatments. A total of sixty patients with TRD were enrolled...

DOI: 10.1007/s00406-024-01913-w Full text Esketamine Anhedonia Cortisol Inflammatory cytokines +5

The Effectiveness of Ketamine Treatment on Depression

Communications in Humanities Research September 27, 2024 Yichen Liu

As the diagnosis rate of depression continues to rise, effective treatment options for this condition have become one of the most researched areas in the field. Earlier antidepressants were primarily developed based on mechanisms that involve regulating imbalanced neurotransmitters. For example, the widely known Selective Serotonin Reuptake Inhibitors (SSRIs) and various tricyclic...

DOI: 10.54254/2753-7064/40/20242334

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.

Journal of Affective Disorders September 15, 2024 David S. Mathai, Thomas D Hull, Leonardo Vando et al. 22 citations

Improving safe and effective access to ketamine therapy is of high priority given the growing burden of mental illness. Telehealth-supported administration of sublingual ketamine is being explored toward this goal. In this longitudinal study, moderately-to-severely depressed patients received four doses of ketamine at home over four weeks within a supportive digital health context. Treatment...

DOI: 10.1016/j.jad.2024.05.131 Full text Depression Ketamine Machine learning Network analysis +2

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

medRxiv Preprint Server September 10, 2024 Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al. 4 citations preprint

Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine’s effects on...

DOI: 10.1101/2024.09.10.24313258 Full text Depression PTSD Ketamine infusions Mental health +7

Dramatic and persistent relief from chronic suicidality, emotional disturbances, and trauma symptomatology with oral ketamine and memantine in refractory depression with complex PTSD

Indian Journal of Psychiatry September 1, 2024 Harsimar Kaur, Chittaranjan Andrade 3 citations

Dear Editor, Ketamine is used off-label for indications ranging from depression to chronic pain. We know of no report of the successful use of oral ketamine, administered without psychotherapy, for complex posttraumatic stress disorder (cPTSD).[1,2] We describe a patient with chronic depression and cPTSD who failed >30 previous interventions but had dramatic and persistent relief from chronic...

DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_587_24

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Molecular Psychiatry September 1, 2024 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al. 23 citations

About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD)...

DOI: 10.1038/s41380-024-02478-9 Full text Treatment-resistant depression Depression treatment Personalized medicine Esketamine therapy +1

Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects?

Molecular Psychiatry September 1, 2024 Brandi Quintanilla, Carlos A. Zarate, Anilkumar Pillai 17 citations

Over 300 million people worldwide suffer from major depressive disorder (MDD). Unfortunately, only 30-40% of patients with MDD achieve complete remission after conventional monoamine antidepressant therapy. In recent years, ketamine has revolutionized the treatment of MDD, with its rapid antidepressant effects manifesting within a few hours as opposed to weeks with conventional antidepressants....

DOI: 10.1038/s41380-024-02507-7 Full text Depression Ketamine Mental health Immunology